Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction (AMICI)
Acute Myocardial Infarction
About this trial
This is an interventional treatment trial for Acute Myocardial Infarction focused on measuring Acute Myocardial Infarction, STEMI, Heart Attack, AMI, Stem Cells
Eligibility Criteria
Key Inclusion Criteria:
- Clinical symptoms consistent with acute myocardial infarct (AMI) (pain, etc.) for a maximum of 12 hours from onset of symptoms to percutaneous coronary intervention (PCI).
- De Novo anterior AMI.
- Successful revascularization of the culprit lesion.
Key Exclusion Criteria:
- Prior AMI, known cardiomyopathy, or hospital admission for heart failure (HF).
- Significant valvular disease.
- Need for other interventional or surgical procedure to treat heart disease (planned or scheduled).
- Cardiogenic shock or hemodynamic instability within 24 hours of randomization.
- Prior PCI to LAD.
- Pacemaker, ICD (Implantable Cardioverter Defibrillator), or any other contra-indication for cardiac MRI.
- Prior or current participation in any stem cell study or any other investigational trial in the past 30 days.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Experimental
Experimental
Placebo
Mesenchymal Precursor Cells (MPC) 12.5 M
Mesenchymal Precursor Cells (MPC) 25 M
Participants received matching-placebo solution 2 milliliters per minute (mL/min) infused Intracoronary for 60 min including line flush [0 Mesenchymal Precursor Cells (MPCs)/min] on Day 0.
Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (2.5x10^5 MPCs/min) on Day 0.
Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (5.0x10^5 MPCs/min) on Day 0.